Moderna stock rally could surge after cancer vaccine data
Moderna’s shares have jumped 650% this year, and a late‑stage melanoma vaccine trial showing a 42% risk reduction could push the rally even higher, analysts say.
Moderna (MRNA) has been the top‑performing stock in the S&P 500 this year, soaring roughly 650% from the start of 2026. The surge follows a late‑stage trial of its experimental cancer vaccine, intismeran, which was tested in combination with Merck’s immunotherapy drug Keytruda. According to The Motley Fool, the trial showed a 42% reduction in the risk of death or disease recurrence for melanoma patients.
The results have ignited optimism among investors, who see the vaccine as a potential new growth engine for a company whose revenue has been sliding. Moderna reported just $1.9 billion in total revenue for 2025, a steep decline from its COVID‑19 peak.
Why it matters to investors
Several factors make the intismeran data significant for shareholders:
Revenue upside: If intismeran can be approved and paired with Keytruda—Merck’s drug that generated $32 billion in revenue last year—Moderna could tap a multi‑billion‑dollar market.
Valuation gap: Merck’s market cap sits near $370 billion, while Moderna’s is under $90 billion. A successful oncology franchise could narrow that gap and justify a higher multiple.
Historical performance: The stock’s 650% gain dwarfs the next best performer, Sandisk, which is up about 380%.
Catalyst potential: CEO Stéphane Bancel has hinted that intismeran could work “everywhere Keytruda works,” opening doors to lung, kidney and other cancers.
Analysts caution, however, that the vaccine is not yet approved and that past financial results have been underwhelming. The market’s enthusiasm is therefore priced on future expectations rather than current earnings.
How it fits into the broader market
The biotech rally comes at a time when broader equity markets are mixed. Earnings week and upcoming midterm elections have created volatility, but strong drug pipeline news often provides a counterbalance. Moderna’s performance illustrates how a single clinical breakthrough can lift an entire sector, especially after years of COVID‑related fatigue.
What to watch next
Investors should keep an eye on three key developments:
Regulatory review: The U.S. Food and Drug Administration’s timeline for evaluating intismeran will be a decisive factor. A positive advisory committee meeting could trigger another price jump.
Further trial data: Additional studies exploring intismeran with Keytruda in other tumor types will test the CEO’s broader claim and could expand the market size.
Financial guidance: Moderna’s upcoming earnings report will reveal whether the company is seeing early commercial traction or if the vaccine’s costs are eroding margins.
While the upside potential is compelling, the stock’s rally is built on forward‑looking assumptions. As The Motley Fool notes, “massive gains at this stage are by no means a guarantee.” Investors should balance enthusiasm with the inherent risks of drug development.
Bottom line for investors and consumers
For investors, Moderna represents a high‑growth biotech play that could benefit from a successful oncology product launch. For consumers, a new vaccine that enhances the efficacy of existing cancer treatments could improve outcomes for patients with melanoma and potentially other cancers. The next few months will be critical in determining whether the current rally is a fleeting spike or the start of a longer‑term ascent.
Japan's services PMI edged up to 51.7 in October, marking five months of growth but missing expectations, with domestic demand strong and cost pressures easing.
Samsung Electronics shares dropped 5%‑7% on Thursday as U.S. chip index fell and AI regulation concerns weighed on the Korean giant, rattling investors.
Qualcomm's Q4 results missed handset revenue expectations, with memory price pressure and Apple modem shifts driving a 4%+ stock drop and prompting cautious outlooks.
